Conventional markers—such as PD-L1 immunohistochemistry (IHC), tumor mutational burden (TMB), and microsatellite instability (MSI)—offer static, region-specific snapshots that often fail to represent dynamic immune status or therapeutic adaptation (33–36). Here, CD274 is linked to neoplasm.